TFMB-(R)-2-HG
Based on 3 publication(s) in Google Scholar
TFMB-(R)-2-HG is a cell membrane-permeable (R)-2-HG and acute myeloid leukemia (AML) oncogenic factor. TFMB-(R)-2-HG competitively inhibits α-ketoglutarate-dependent dioxygenases such as KDM2B and FTO. TFMB-(R)-2-HG impairs cell differentiation in response to Estrogen withdrawal. TFMB-(R)-2-HG is used in acute myeloid leukemia and glioma research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.26%
- CAS. Nr.: 1445700-01-5
- Formel: C13H11F3O4
- Molecular Weight:288.22
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) TFMB-(R)-2-HG
More
Biologische Aktivität
Beschreibung
IC50 & Target
Carcinogenic factor[1]
In Vitro
TFMB-(R)-2-HG (100-500 μM; multiple passages of treatment) promotes growth factor-independent growth of TF-1 cells and inhibits their response to erythropoietin (EPO) in a dose- and passage- dependent manner[1].
TFMB-(R)-2-HG (3 mM) significantly enhances the anchorage-independent growth of N::TVA;Cdkn2alox/lox;Atrxlox/lox;Ptenlox/lox astrocytes[2].
TFMB-(R)-2-HG (500 μM; 21 days) can significantly suppress global 5hmC levels in TF-1 cells and transform TF-1 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 1445700-01-5
-
Appearance Solid
-
Molecular Weight 288.22
-
Formel C13H11F3O4
-
Color White to off-white
-
SMILES
O=C([C@@H](CC1)OC1=O)OCC2=CC=CC(C(F)(F)F)=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Immunity
NLRP3-mediated glutaminolysis controls microglial phagocytosis to promote Alzheimer's disease progression. [Abstract]2025 Jan 31:S1074-7613(25)00032-9. PMID: 39904338 -
Clin Cancer Res
UBE2T-mediated HP1α ubiquitination enhances nucleolar function and promotes the progression of IDH1/TP53-mutant glioma. [Abstract]2025 Jul 8. PMID: 40627452 -
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 233.33 mg/mL (809.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
iPSC cell differentiation
Induced pluripotent stem cells (iPSCs) are a type of cell that has similar properties to embryonic stem cells through somatic cell reprogramming.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Losman JA, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013 Mar 29;339(6127):1621-5. [Content Brief]
[2]. Philip B, et al. Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Rep. 2018 May 1;23(5):1553-1564. [Content Brief]
[3]. Gunn K, et al. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers. Cancer Discov. 2023 Jun 2;13(6):1478-1497. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4696 mL | 17.3478 mL | 34.6956 mL | 86.7390 mL |
| 5 mM | 0.6939 mL | 3.4696 mL | 6.9391 mL | 17.3478 mL | |
| 10 mM | 0.3470 mL | 1.7348 mL | 3.4696 mL | 8.6739 mL | |
| 15 mM | 0.2313 mL | 1.1565 mL | 2.3130 mL | 5.7826 mL | |
| 20 mM | 0.1735 mL | 0.8674 mL | 1.7348 mL | 4.3369 mL | |
| 25 mM | 0.1388 mL | 0.6939 mL | 1.3878 mL | 3.4696 mL | |
| 30 mM | 0.1157 mL | 0.5783 mL | 1.1565 mL | 2.8913 mL | |
| 40 mM | 0.0867 mL | 0.4337 mL | 0.8674 mL | 2.1685 mL | |
| 50 mM | 0.0694 mL | 0.3470 mL | 0.6939 mL | 1.7348 mL | |
| 60 mM | 0.0578 mL | 0.2891 mL | 0.5783 mL | 1.4456 mL | |
| 80 mM | 0.0434 mL | 0.2168 mL | 0.4337 mL | 1.0842 mL | |
| 100 mM | 0.0347 mL | 0.1735 mL | 0.3470 mL | 0.8674 mL |
TFMB-(R)-2-HG Related Classifications
HY-129079 Related Classifications
Powered by Bioz